Your body is adjusting to increasing levels of GLP-1 receptor activation, and the first few days after each dose increase tend to be the roughest
Although, at first glance, it is easy to overestimate the findings and assume they apply to everyone, this studys participants were a very specific group: older adults with type 2 diabetes
Novo Nordisk, Pfizer and other big pharma companies have just taken [the hormone] GLP-1 itself, and spent 20 years stabilising the peptide, making it druggable, so its not broken down [in the body], explains John Unitt, vice president of immunology and inflammation drug discovery at Sygnature Discovery in Nottinghamshire, UK, and a GPCR drug discovery expert
Nathanson D, Erdogdu O, Pernow J, Zhang Q, Nystrm T
GLP-1 drugs lower blood sugar only when it's high, unlike insulin, which works regardless of glucose levels
doi: 10.1128/MCB.24.5.1844-1854.2004